MAPT and Alzheimer disease: In blood samples, OGG1 mRNA levels were lower in AD patients compared to healthy controls already in early disease stages and in patients with abnormal and normal cerebrospinal fluid levels of Aβ-42/Tau, suggesting that alteration in the OGG1 mRNA profile may occur independent of plaque/Tau pathology and is an event preceding AD.